Skip to content

US · PRE · MEDICAL - DIAGNOSTICS & RESEARCH

Prenetics Global Limited (PRE) intrinsic value and stock valuation

$8.80as of 2026-11-21 · Mkt cap 313.83M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Prenetics Global Limited DCF and intrinsic value

InvestorsCraft values PRE with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PRE’s statements →

Prenetics Global Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Hong Kong prenetics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$92.4M+7.2% 5y CAGRd
20192025
Net income
-$-37.71M
20192025
Free cash flow
-$-22.02M
20192025
Total equity
$174.5M+41.3% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$92.4M$30.6M$21.7M$13.2M$12.5M
Operating income-$-38.13M-$-48.14M-$-51.91M-$-66.02M-$-56.66M
Net income-$-37.71M-$-46.3M-$-62.72M-$-190.45M-$-174.01M
EPSd-$-2.68M-$-3.64M-$-5.58M-$-37.56M-$-47.03M
Operating cash flow-$-21.81M-$-28.87M-$-13.76M$14.5M$13.4M
Capital expenditure-$-210K-$-1.06M-$-910K-$-6.34M-$-11.41M
Free cash flow-$-22.02M-$-29.94M-$-14.68M$8.17M$2M
Total assets$203.5M$213.6M$254.2M$312.1M$148.5M
Total debt$2.2M$5.77M$2.37M$6.65M$491.7M
Net debt-$-29.93M-$-46.48M-$-43.34M-$-140.01M$456.4M
Total equity$174.5M$171.4M$210.2M$243.5M-$-400.89M
Cash and short-term investments$61.5M$62.8M$72.7M$184.1M$45.2M
Income statement
20252024202320222021
Revenue$92.4M$30.6M$21.7M$13.2M$12.5M
Cost of revenue$43.6M$15.2M$12.9M$9.55M$8.93M
Gross profit$48.8M$15.4M$8.83M$3.62M$3.6M
Research and development expenses$5.13M$10.9M$11.7M$5.99M$6.39M
Selling, general and administrative expenses$79.8M$55.4M$49.7M$64.1M$53.7M
Other expenses$1.99M-$-2.75M-$-610K-$-430K$200K
Operating expenses$86.9M$63.5M$60.7M$69.6M$60.3M
Cost and expenses$130.5M$78.8M$73.7M$79.2M$69.2M
Interest income$1.04M$2.04M$3.92M$470K$0.00
Interest expense$240K$200K$120K$240K$40K
Depreciation and amortization$3.78M$5.93M$7.79M$7.54M$7.35M
Ebitda-$-32.19M-$-51.57M-$-47.9M-$-218.04M-$-209.16M
Operating income-$-38.13M-$-48.14M-$-51.91M-$-66.02M-$-56.66M
Total other income/expenses, net$1.92M-$-9.56M-$-4.76M-$-159.8M-$-159.89M
Income before tax-$-36.21M-$-57.7M-$-56.67M-$-225.82M-$-216.55M
Income tax expense$30K-$-7.87M-$-270K-$-240K$2.57M
Net income-$-37.71M-$-46.3M-$-62.72M-$-190.45M-$-174.01M
Weighted average shares outstanding$14.1M$12.7M$11.3M$5.07M$3.7M
Weighted average diluted shares outstanding$14.1M$12.7M$11.3M$5.07M$3.7M
Balance sheet
20252024202320222021
Cash and short-term investments$61.5M$62.8M$72.7M$184.1M$45.2M
Net receivables$2.98M$5.61M$5.29M$42.5M$47.1M
Inventory$7.06M$6.57M$3.13M$4.53M$6.83M
Total current assets$83.4M$86.2M$93.7M$241.8M$106.9M
Property, plant and equipment, net$1.76M$7.81M$5.78M$13.1M$13M
Goodwill and intangible assets$44.7M$48.9M$42.6M$48.6M$27.8M
Long-term investments$67M$69.3M$107.8M$790K$0.00
Total non-current assets$120.1M$127.4M$160.5M$70.3M$41.6M
Total assets$203.5M$213.6M$254.2M$312.1M$148.5M
Accounts payable$7.72M$3.67M$1.67M$7.29M$9.98M
Short-term debt$1.33M$2.76M$1.5M$2.88M$1.67M
Deferred revenue$3.09M$6.49M$6.11M$5.67M$9.59M
Total current liabilities$27.7M$36.6M$39.5M$57.2M$58.7M
Long-term debt$870K$3.01M$870K$3.76M$490M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.34M$5.68M$4.53M$11.5M$490.7M
Capital lease obligations$440K$5.77M$2.37M$6.65M$3.6M
Total liabilities$29M$42.2M$44M$68.7M$549.4M
Common stock$30K$20K$20K$10K$0.00
Retained earnings$0.00-$-517.07M-$-470.77M-$-408.04M$0.00
Accumulated other comprehensive income (loss)$0.00-$-169.25M-$-176.03M-$-185.69M-$-400.81M
Total equity$174.5M$171.4M$210.2M$243.5M-$-400.89M
Total investments$96.4M$79.9M$134.9M$38.3M$9.91M
Total debt$2.2M$5.77M$2.37M$6.65M$491.7M
Net debt-$-29.93M-$-46.48M-$-43.34M-$-140.01M$456.4M
Cash flow statement
20252024202320222021
Net income-$-52.7M-$-49.81M-$-64.78M-$-190.45M-$-174.02M
Depreciation and amortization$3.78M$5.93M$7.79M$7.54M$7.35M
Stock-based compensation$0.00$12M$10.6M$31.6M$22.5M
Change in working capital$6.62M$1.97M$24.2M-$-33.76M-$-6.59M
Accounts receivable-$-530K-$-430K$37.6M$6.97M-$-24.06M
Inventory-$-3.38M$1.32M-$-1.73M$1.26M-$-2.33M
Accounts payable$4.91M-$-4.68M-$-5.62M-$-2.63M-$-3.46M
Net cash provided by operating activities-$-21.81M-$-28.87M-$-13.76M$14.5M$13.4M
Investments in property, plant and equipment-$-54.56M-$-1.01M-$-350K-$-6.34M-$-8.55M
Acquisitions, net$37.8M$21.7M$0.00-$-3.42M$0.00
Net cash used for investing activities-$-35.79M$38.5M-$-82.95M-$-46.14M-$-22.02M
Common stock issued$0.00$0.00$0.00$120K$0.00
Common stock repurchased$0.00-$-580K-$-1.23M-$-660K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$37.5M-$-3.34M-$-4.7M$143.3M$29.3M
Net change in cash-$-20.12M$6.54M-$-100.95M$111.4M$20.8M
Cash at end of period$32.1M$52.3M$45.7M$146.7M$35.3M
Operating cash flow-$-21.81M-$-28.87M-$-13.76M$14.5M$13.4M
Capital expenditure-$-210K-$-1.06M-$-910K-$-6.34M-$-11.41M
Free cash flow-$-22.02M-$-29.94M-$-14.68M$8.17M$2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Prenetics Global Limited

        As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.

        CEO
        Sheng Wu Yeung
        Employees
        98
        Beta
        0.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Prenetics Global Limited (PRE)?

        Prenetics Global Limited (PRE) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PRE undervalued?

        PRE trades at a price of $8.80 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.